Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (29689)	12/16/1999 3:50:00 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

I think there was something new. I do not recall Ligand referring to mammary tumors in general in the past. As I recall, they have always qualified it. To me, this suggests they know more about how Targretin acts and that could mean a higher level of confidence that the results will be comparable in humans. If these sorts of results are confirmed for humans, life will get interesting indeed. Besides, whatever happened to the successor compounds? It's been a while since I've heard any mention of other compounds and Ligand does have a few more in the pipeline... Thanks, Torben